Acerus is a Canadian pharmaceutical company focused on the development, manufacture, marketing and distribution of innovative, branded products that improve the patient experience.
Founded in 2008, Acerus has quickly grown into a fully integrated company with expertise in all stages of the pharmaceutical product lifecycle. During the first few years, the Company focused its efforts on internal product development. In 2014, the Company had a breakout year, achieving several significant milestones. The achievements included the approval and out-licensing of a testosterone replacement therapy utilizing a novel drug delivery platform for the U.S. market, and the completion of a Phase II study for a potential ‘first in class’ product for female orgasmic disorder. Also of note in 2014 was the Company’s acquisition of a revenue-generating asset on the Canadian market.